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Although increasingly aggressive decompression and resection methods have resulted in improved outcomes for patients with
metastaticspine disease, these aggressive surgeries are not feasible for patients with numerous comorbid conditions.Such patients
stand to beneﬁt from management via minimally invasive spine surgery (MIS), given its association with decreased perioperative
morbidity. We performed a systematic review of literature with the goal of evaluating the clinical eﬃcacy and safety of MIS in
the setting of metastatic spine disease. Results suggest that MIS is an eﬃcacious means of achieving neurological improvement
and alleviating pain. In addition, data suggests that MIS oﬀers decreased blood loss, operative time, and complication rates in
comparison to standard open spine surgery. However, due to the paucity of studies and low class of available evidence, the ability
to draw comprehensive conclusionsis limited. Future investigations should be conducted comparing standard surgery versus MIS
in a prospective fashion.
1.Introduction
It is estimated that nearly 10 million people worldwide were
diagnosed with cancer in 2000, with the incidence expected
to increase to 15 million by 2020 [1]. The most commonly
diagnosed neoplasms are breast, lung, and prostate cancers
[2, 3]. Metastatic invasion of the spinal column can occur
via various mechanisms that are dependent on both the bio-
logical behavior and physical location of the primary tumor
[4]. Given the predilection of the breast, prostate, and lung
neoplasms to metastasize to bone, it is not surprising that
spinal metastases occur in 30–90% of patients, with 10% of
such patients experiencing symptomatic metastatic epidural
spinalcordcompression(MESCC)[4,5].Themostcommon
symptom at presentation is pain that can be both radicular
(exaggerated by percussion or palpation) and/or mechanical
(exacerbated by movement) [6, 7]. Neurological dysfunction
including motor, sensory, and autonomic dysfunction is
the second most common presentation modality and is
indicative of metastatic epidural spinal cord compression
(MESCC) [3, 8–10].
Ideal management is multidisciplinary and involves vari-
ous medical specialties such as neurosurgery, surgical oncol-
ogy, medical oncology, radiation oncology, interventional
radiology, pain specialists, and rehabilitation therapy [4, 5].
Management strategies involve a combination of surgery
(forcandidatepatients),radiotherapy, andpharmacotherapy
[4, 5, 11]. Due to both the short life expectancy of aﬄicted
patients and high systemic tumor burden [8, 9, 12–14],
with the exception of solitary metastatic lesions such as
in the setting of renal cell carcinoma, treatment regimens
are most often palliative rather than curative [10]. Aﬄicted
patients frequently present with inﬁltration of the spinal
column with tissues that lack weight bearing properties
resulting in spinal instability, particularly ventral column
instability given that most metastatic lesions localize to the
anterior elements [11]. Optimal treatment of such patients
requires stabilization in addition to traditional (surgical or
nonsurgical) decompression [4, 15]. The most eﬃcacious
modality for restoring column instability is reconstructive
surgical intervention. Unfortunately, numerous patients are
not considered candidates for surgical intervention due to2 International Journal of Surgical Oncology
neoplasm-associated comorbidities such as malnourishment
and diminished immune system that make extensive surgical
procedures unfeasible [4]. Such patients can be managed
with vertebral augmentation, as it can provide some degree
ofrestabilization[11].However,surgicaladvancesintheﬁeld
of minimally invasive spine surgery (MIS) have opened the
door for not only extended surgical candidacy to patients
who were previously ineligible, but it has also established the
setting for surgical intervention with minimal perioperative
morbiditysuch asdecreasedpain,lessbloodloss, andshorter
hospital stays [11, 15–23]. This paper aims to describe the
current role of MIS in the treatment of metastatic spine
disease. The overall objectives of this paper are to present a
systematic review of literature with regard to the following
clinical questions:
(1) the eﬃcacy of MIS in improving neurological and
pain-associated outcomes in the setting of metastatic
spine disease;
(2) the incidence of complications associated with MIS
in the setting of metastatic spine disease.
2.Methods
2.1. Search Strategy. A systematic review of literature was
performed employing Pubmed and a review of bibliogra-
phies of reviewed articles. The search query was broad
and formulated to combine a number of subheadings and
keywords that included the therapies and pathology of
interest. The search string employed was the following:
(“Minimally Invasive Surgery” OR “MIS” OR “VAST”
OR “endoscopic thoracoscopy” OR “mini-open spine
surgery” OR “minimal access spine surgery” OR “MASS”)
AND ((“bone neoplasms” (Mesh) OR “spinal neoplasms”
(Mesh)) OR (“spin∗”A N D“ m e t a s t a ∗”) OR (“Spinal Cord
Compression” (Mesh) OR “spinal cord compression”) OR
(“epidural neoplasms” (Mesh) OR “epidural neoplasm”)).
2.2. Eligibility Criteria
(i) Criteria for possible inclusion were the following:
(a) articles published between 1980 and 2011,
(b) all articles in English or with an English trans-
lation,
(c) adult age group (18 years and older),
(d) articles describing the use of minimally invasive
spine surgery modalities in the treatment of
metastatic disease,
(e) fully published peer reviewed studies including
RCTs, nonrandomized trials, cohort studies,
case control studies, case series, and case
reports. Both prospective and retrospective
studies were considered.
(ii) Criteria for exclusion were the following:
(a) iontradural spine tumors,
(b) primary spine tumors,
(c) pediatric age groups,
(d) articles with no extractable data speciﬁc to
metastatic spine disease.
2.3. Study Eligibility and Quality Assessment. Abstracts were
screened by two independent reviewers using the above-
stated inclusion and exclusion criteria. Cases of reviewer
disagreement were resolved by a third reviewer. Full-text
versions of acceptable article were gathered and subjected
to more detailed screening for inclusion. After ﬁnalizing a
collection of eligible studies, the studies were analyzed in
detail, and the data pertaining to the research questions was
extractedandtabulatedbyonereviewer.Thesecondreviewer
checked the extracted information.
3.Results
A total of eleven publications were ultimately found eligible
to evaluate the clinical outcomes associated with MIS as
a treatment for metastatic spine disease. All of the publi-
cations available were retrospective in nature. Nine of the
publications were retrospective case series, and two of the
publications were case reports. Although case reports are
normally excluded in systematic reviews, they were included
in this review due to the paucity of evidence evaluating MIS
in thesetting of metastatic spine disease. The main outcomes
extracted from the selected publications included mean
operating time (MOT), mean blood loss (MBL), hospital
length of stay (LOS), rate of neurological improvement
(NI), pain alleviation rate (PA), and complication rate (CR).
Collected outcomes are tabulated in Tables 1 and 2.
3.1. Video-Assisted Thoracostomy (VAST). There were a
total of ﬁve publications addressing the use of VAST
or endoscopy-assisted posterior decompression to manage
patients with metastatic spine lesions. Four of the publica-
tionswereretrospectivecaseseries,andonewasacasereport.
The earliest description of VAST for managing metastatic
vertebral was published by Rosenthal et al. [20] in 1996.
The authors described the development of an endoscopic
procedure to achieveanterior vertebrectomy, reconstruction,
and stabilization of the thoracic spine in 4 patients aﬄicted
withmetastaticspinelesions.Allpatientswereingoodhealth
condition but were experiencing progressive neurological
decline and radiological evidence of bone destruction and
cord compression. The study reported a 6.5hr MOT, 7.5 day
LOS, and 1450mL MBL. The authors found that MBL was
correlated to MOT and extent of vertebrectomy. Addition-
ally, all of the patients were ambulatory with assistance on
postoperative day 1, ambulatory with a Jewett brace during
theﬁrst 4weeks,andindependentlyambulatoryat11-month
followup (NI: 100%). Patients were pain-free following chest
drain removal on day 3 or 4 and remained pain-free atInternational Journal of Surgical Oncology 3
Table 1: Endoscopic video-assisted thoracoscopy (VAST) outcomes. MOT: Mean operating time; LOS: Length of stay; NI: Neurological
improvement rate; PA: Pain alleviation rate; CR: Complications rate; MBL: Mean blood loss.
Study Design and procedure Outcome results
Rosenthal et al. [20];
1996
Retrospective analysis (n = 4) of outcomes associated
with VAST MIS management of thoracic metastatic
spine disease
MOT: 6.5 hours
LOS:median 7.5 days
NI: All patients experienced neurological improvement;
in addition, all were independently ambulatory at time
discharge and followup (mean 11mo.)
PA: All patients free of pain at time of discharge and
followup (mean 11mo)
CR: none
MBL = mean 1450mL
Huang et al. [24] Retrospective analysis (n = 41) to analyze the
complication rate in VAST MIS
MOT: 3.1 hours
CR: 54%
MBL: mean 775mL
Le Huec et al. [25],
2001
Case series (n = 2) to report outcomes associated with
the use of VAST to manage spinal metastases at the
cervicothoracic junction
MOT: 2.6 hours
NI: Both patients experienced neurological
improvement and were independent at followup (mean
9.5mo)
PA: Both patients experienced pain relief and only one
required narcotics postoperatively
CR: 1 patient suﬀered a progressive recurrent laryngeal
nerve palsy
MBL: 350mL
McLain [21], 2001
Retrospective case series (n = 8) to evaluate outcomes
of endoscopy-assisted posterolateral approach to
manage thoracic metastatic spine disease
MOT: 6 hours
LOS: 6.5 days
NI: All 8 patients experienced neurological
improvement
PA: All 8 patients experienced pain relief. Additionally
63% of patients experienced complete pain relief
CR: none
MBL: 1677mL
Mobbs et al. [26],
2002
Case report (n = 1) of endoscope-assisted posterior
decompression of a solitary renal cell carcinoma
metastatic lesion
NI: Patient was neurologically intact at two-month
followup. Patient initially presented with hyperreﬂexia
PA: Patient was pain-free at two-month followup
CR: Patient experienced no procedural complications
11-month followup (PA: 100%). The study reported no
complications (Table 1).
Huang et al. [24] published a retrospective case review
of 90 patients who had undergone VAST for various spinal
pathologies, of which 41 cases were due to metastatic
lesions. The main goal of the study was to evaluate MIS
complication rates. Procedures performed for the metastatic
lesion aﬄicted subgroup included biopsy only, corpectomy
for decompression, and corpectomy with interbody fusion.
Although the study did not stratify MOT (3.1h) or MBL
(775mL)accordingtoneoplasticornonneoplasticetiologies,
the study did stratify complication rates. The authors
reported a total of 30 complications in 22 patients (overall
CR: 33%) for the 90 procedures performed. Importantly,
22 of those complications occurred among the 41 patients
treated for metastatic spine disease (CR: 54%). Additionally,
the authors also noted that the most common complication
was excessive intraoperative bleeding, with all 5 instances
occurring in patients with metastatic disease. The additional
complicationsencountered were intercostals neuralgia (7%),
superﬁcial wound infection (7%),a t e l e c t a s i s( 5 % ) ,p e r i c a r -
dial penetration (2%),implant failure (2%),and death(2%).
Notably,none of the complications occurred due to injury to
the spinal cord, a great vessel, or internal organ (Table 1).
Le Huec et al. [25] published a small case series of two
patients in which VAST was used to manage metastatic spine
disease encompassing the cervicothoracic junction. The goal
of the authors was to develop an alternative approach to
the traditional lateral approach that requires mobilization
of the scapula to visualize the T1, T2, and T3 spinal
levels. The technique was technically feasible and allowed
for ample access to achieve corpectomy and visualization
of the posterior longitudinal ligament, thereby allowing for
complete release of the cord. MOT was 2.6 hours, MBL was
350mL, and meanLOS was 6.5days.Bothpatientspresented
withprogressiveneurologicaldeclinebutwereindependently
ambulating at last followup (7 and 12 months) (NI: 100%).
Bothpatients experienced substantial pain relief (PA: 100%),
but one required narcotics at the followup due to having
undergone additional surgeries for other metastases. One4 International Journal of Surgical Oncology
patientacquiredaprogressive recurrentlaryngeal nervepalsy
(CR: 50%) (Table 1).
3.2. Endoscopy-Assisted Posterior Decompression. McLain
[21] reported a retrospective case series of 8 patients aﬄicted
with metastatic spine lesions to demonstrate the feasibility of
endoscopically assisted (transpedicular) decompression and
stabilization through a single, extrapleural, and posterolat-
eral approach. MOT was 6.5 hours, and MBL was 1677mL.
All 6 of the patients that presented with neurological deﬁcit
recovered completely and maintained neurological integrity
until the last followup or terminal care (3–36 months) (NI:
100%). The other 2 patients not presenting with neurologic
compromise retained neurological function until the last
followup or terminal care (3–36 months). All 8 patients
experienced pain relief (PA: 100%), and 5 patients (62.5%)
did not require any analgesics at the last followup. The
authors concludedthat endoscopy augmented the eﬃcacy of
theposterolateral approachbyimproving thevisualization of
structures that were traditionally diﬃcult to access through a
standard posterolateral approach (Table 1).
Mobbs et al. [26] published a case report of endoscope-
assisted posterior decompression of a solitary renal cell
carcinoma metastatic lesion. The patient initially presented
with hyperreﬂexia and back pain but was neurologically
intact and pain-free at two-month postoperative followup.
The patient’s course was uncomplicated throughout the
procedure and postoperative recovery (Table 1).
3.3. Minimal Access Spine Surgery (MASS). There were a
total of six publications addressing the use of MASS to
manage patients with metastatic spine lesions. Muhlbauer et
al.[27]publishedtheﬁrst descriptionofMASSformanaging
metastatic spine disease in 2000. The authors reported a
small retrospective case series regarding the management of
5 patients with compression fractures from osteoporosis or
metastatic lesions. Reported MOT was 6 hours, and MBL
was 1120mL. All 5 of the patients presented preoperatively
with both pain and neurological dysfunction. At followup,
all patients had experienced neurological improvement (NI:
100%) characterized by either progressing from ambulating
with a cane to ambulating unassisted, or from being
nonambulatory to ambulating with a cane. Additionally, all
patients experienced signiﬁcant pain relief (PA: 100%) with
40%ofthe patientsnot utilizinganalgesics at followup (6–12
months) (Table 2).
Huang et al. [23] published a retrospective analysis of
46 patients to compare outcomes in MASS (n = 29)
and standard thoracotomy (ST, n = 17) in the setting of
metastatic spine disease. There was no signiﬁcant diﬀerence
in MOT, MBL, NI, or CR. MOT for MASS was 179 minutes
versus 180 minutes for ST (P = .54). MBL for MASS was
1,100mL versus 1,162mL for ST (P = .63). Neurological
outcome was reported as the postoperative reacquisition
of ambulation. NI for MASS was 70.8% versus 69.2% for
ST (P = .6). CR for MASS was 24% versus 29% for ST
(P>. 05). Complications encountered from MASS included
dural tears (2), femoral fracture (1), pneumothorax (1),
tumor recurrence (1), implant failure (1), and metastasis
(1). Complications encountered from ST included sepsis
(1), postoperative pneumonia (1), pneumothorax (1), GI
bleeding (1), and UTI (1). Additionally, 2 year survival
rates were also not signiﬁcantly diﬀerent (MASS: 24% versus
ST: 29%, P = .69). However, the authors found that the
percentageofpatientsrequiringatleasta2-daypostoperative
admission to the intensive care unit (ICU) was signiﬁcantly
diﬀerent when comparing MASS to ST, with MASS resulting
in signiﬁcantly less admissions (MASS 6.9% versus ST: 88%,
P ≤ .001) (Table 2).
Deutsch et al. [28] reported a retrospective case series
of 8 patients undergoing MASS posterolateral vertebrectomy
and decompression to treat symptomatic thoracic MESCC.
The patient population was compromised of patients not
deemed candidate for conventional open thoracotomy due
to age (mean 74y), limited life expectancy, and/or systemic
m e t a s t a t i cb u r d e n .M O Tw a s2 . 2h o u r sa n dM B Lw a s
227mL. All patients presented with substantial neurologic
deﬁcit (mean Nurick grade: 4.35 (range 3–5)) and pain
(mean numerical pain score (NPS) 5.5 (range 3–8)). Post-
operatively, 5 patients experienced neurologic improvement
(NI: 62.5 %), and the mean Nurick grade of all patients
decreased to 3.13. 5 patients experienced pain alleviation
(PA: 62.5%), with the group mean NPS decreasing to 3.10.
There was no incidence of complications reported (Table 2).
Kan and Schmidt [29] published a retrospective case
series of 5 patients with metastatic disease of the thoracic
spine who underwent ventral decompression via MASS.
The procedure included a corpectomy, interbody fusion,
expandable cage-mediated reconstruction, and stabilization
via anterior plating through MASS techniques. MOT was
4.3 hours, MBL was 610mL, and mean LOS was 6.25 days.
All patients who presented with neurological deﬁcits were
neurologically intact at 6-month followup (NI: 100%). The
preoperating mean VAS score for the group was 6.8, and it
decreased to3at6-month followup.Additionally,all patients
experienced some degree of pain relief (PA: 100%) (Table 2).
Payer and Sottas [30] published a case series of 37
patients, 11 of which were aﬄicted with thoracic metastasis
to the spine and managed via MASS using the SynFrame
(Stratec Medical; Obendorf, Switzerland) table mounted
retractor. The authors stratiﬁed results according to tumor
and nontumor etiology. MOT for tumor patients was 188
minutes versus 178 minutes for nontumor patients. MBL
for tumor patients was 711mL versus 598mL for nontumor
patients. There were 4complications (15%)in the nontumor
group and 2 complications in the tumor group (18%). Neu-
rological outcomes were not stratiﬁed according to etiology.
However, it was reported that of the 22 patients presenting
with neurologicaldeﬁcits,20patientsdemonstrated recovery
(NI: 92%). Preoperative and postoperative pain outcomes
were not compared (Table 2).
Taghva et al. [31] published a case report describing a
T4 and T5 vertebrectomy with expandable cage placement
coupled with T1–T8 screw ﬁxation and fusion using MASS.
The patient was aﬄicted with metastatic adenocarcinoma
of the lung and presented with back pain for more than 4
months.Onneurologicalexamination, thepatientwasfoundInternational Journal of Surgical Oncology 5
Table 2: Minimal access spine surgery outcomes. MOT: Mean operating time; LOS: Length of stay; NI: Neurological improvement rate; PA:
Pain alleviation rate; CR: Complications rate; MBL: Mean blood loss, SVR: 2-year survival rate.
Study Design and procedure Outcome results
M¨ uhlbauer et al. [27],
2000
Retrospective case series (n = 5) of patients undergoing
lumbar corpectomy and anterior reconstruction via
MASS in the setting of osteoporotic or
malignancy-related compression fractures
MOT: 6 hours
NI: All patients experienced neurological improvement
and were ambulatory at followup (6mo to 1yr)
PA: All patients experienced pain relief. 40% of patients
did not utilize analgesics at 1-year followup
CR: Segmental vessel nick via a high-speed drill.
Bleeding was adequately controlled
MBL: 1120mL
Huang et al. [23],
2006
Retrospective analysis (n = 46) comparing MASS
(n = 29) to standard thoracotomy (ST) (n = 17) in the
management of thoracic spinal metastasis
MOT: MASS = 179 mins versus ST = 180 mins; P = .54
%R e q u i r i n g2 - d a yI C Us t a y :M A S S= 6.9% versus ST =
88%, P ≤ .001
NI: Reacquisition of ambulation postoperatively; MASS
= 70.8% versus ST = 69.2%, P = .6
SVR: MASS = 27.4mo versus ST = 24.8mo, P = .68
CR: MASS = 24% versus ST = 29%
MBL: MASS = 1,100mL versus ST = 1,162mL, P = .63
Deutsch et al. [28],
2008
Retrospective case series (n = 8) of patients undergoing
MASS posterolateral vertebrectomy and decompression
for the managementof thoracic spinal metastasis
MOT: 2.2 hours
LOS: 4 days
NI: 62.5% of patients
PA: 62.5% of patients
CRs: none
MBL: 227mL
Kan and Schmidt
[29], 2008
Retrospective case series (n = 5) of patients undergoing
MASS anterior corpectomy and decompression for the
management of thoracic spinal metastasis
MOT: 4.3 hours
LOS:6.25
NI: All patients experienced neurological improvement
PA: All patients experienced pain alleviation
CR: none
MBL: 610mL
Payer and Sottas [30],
2008
Retrospective case series (n = 11) analyzing operative
outcomes of MASS conducted with the SynFrame
(Stratec Medical, Obendorf, Switzerland) table
mounted retractor in the setting of thoracic metastatic
spine disease
MOT: 188mins
NI: All patients neurologically intact, at presentation
remained intact and 91% of patients with preoperative
deﬁcit experienced neurological improvement
CR: 18% (2/11; one dural tear and one superﬁcial
wound infection)
MBL: 711mL
Taghva et al. [31],
2010
Case report of a man undergoing vertebrectomy and
expandable cage reconstruction for the management of
metastatic lung adenocarcinoma localized to the
thoracic spine
MOT: 7 hours
LOS: 5 days
NI: Patient experienced myelopathy relief and was
ambulatory on postoperative day 1
PA: at 9-month followup, patient remained back
pain-free with no use of analgesic medications
CR: none
MBL: 1200mL
tohavedecreased strength and sensation. Operative timewas
7 hours, and blood loss was 1200mL. The patient was dis-
charged 5 days following surgery. Neurological outcome was
positive, with the patient being ambulatory postoperatively
on day 1 and completely recovering strength and sensory
function at9-month followup.Similarly, pain alleviationwas
satisfactory with the patient reported to be pain-free at 9-
month followup (Table 2).
3.4. Summary. There were a total of 5 publications, encom-
passing a total of 105 patients, selected to review the
outcomes of VAST and endoscopy-assisted posterior decom-
pression in the setting of metastatic spine disease. Data was
compiled and yielded a median MOT of 4.6 hours (2.6–
6.5 hours), a median MBL of 1113mL (350–1677mL), 7-
day median LOS (6.5–7.5 days), 100% median NI (92%–
100%), 100% median PA (94%–100%), and 0% median CR
(0%–54%) (Table 3) Data gathered from the 6 publications,
totaling 76 patients, to evaluate MASS outcomes in the
setting of metastatic spine disease yieldedsimilar results with
a median MOT of 3.7 hours (2.2–7 hours), a median MBL
of 905mL (227–1200mL), 5-day median LOS (4–6.25 days),6 International Journal of Surgical Oncology
Table 3: Minimally invasive spine surgery outcomes summary.
VAST: Video-assisted thoracoscopy; MASS: Minimal access spine
surgery; mMOT: Median mean operating time; mLOS: Median
mean length of stay; NI: Median neurological improvement rate;
PA: Median pain alleviation rate; mCR: Median complication rate;
mMBL: Median mean blood loss.
VAST (median (range)) MASS (median (range))
N = 105 patients 76 patients
mMOT 4.6 hours (2.6–6.5 hours) 3.7 hours (2.2–7 hours)
mLOS 7 days (6.5–7.5 days) 5 days (4–6.25 days)
mNI: 100% (92%–100%) 95% (62.5%–100%)
mPA: 100% (94%–100%) 100% (62.5%–100%)
mCR: 0% (0%–54%) 9% (0%–24%)
mMBL 1113mL (350–1677mL) 905mL (227–1200mL)
95% median NI (62.5%–100%), 100% median PA (62.5%–
100%), and 9% median CR (0%–24%) (Table 3). In com-
paring VAST to MASS (Table 3), the data suggests that
VAST was associated with longer operative times, increased
hospital length of stay, and increased blood loss. However,
VAST compared favorably when looking at median neuro-
logicalimprovementandmediancomplicationrates.Despite
appearing clinically signiﬁcant, it is uncertain whether these
diﬀerences are statistically signiﬁcant.
4.Discussion
Surgicalinterventioninthesettingofmetastaticspinedisease
commenced prior to the advent of radiotherapy, and the
initial goals of treatment were to achieve decompression of
the spinal cord. This was most commonly performed via a
dorsal laminectomy, as it was believed that this would relieve
the pressure on the cord resulting in a reversal of neurologic
deﬁcits. However, the majority of metastatic neoplasms
aﬀect the anterior column and thus when combined with
destabilization of the posterior column via a laminectomy,
patients experienced rapiddestabilization oftheentire spinal
column along with both cord vascular insuﬃciency and
radicular compression due to the loss of spinal column
integrity [2, 32].
With the advent of radiotherapy, evidence accrued
demonstrating no neurological beneﬁt to surgical inter-
vention, speciﬁcally laminectomy alone, in comparison to
radiotherapy alone, and thus surgery as a primary treatment
modality was abandoned [33–36]. However, spine surgery
in the setting of the metastatic spine disease continued
to advance as surgeons continued to operate in patients
whose neurological function was not improved following
radiotherapy [11]. During the 1980s, rapid advances in both
surgical technique and advances in spinal instrumentation
resulted in the publication of the studies that re-established
a role for surgical intervention as an addition to radio-
therapy [37, 38]. In 1983, Constans et al. [39] published a
retrospective case series of 600 patients with symptomatic
MESCC and reported a neurological stabilization rate of
41% and a neurological improvement rate of 44%, both of
which were rates considered to be superior to prior reported
rates. In 2004, Klimo Jr. et al. [40] published a meta-analysis
comparing outcomes of surgery and radiotherapy manage-
ment compared to radiotherapy alone and reported superior
outcomes for patients who underwent surgery in addition
to radiotherapy. In 2005, Patchell et al. [41] conducted
the ﬁrst randomized control study comparing the eﬃcacy
of radiotherapy and surgery to that of radiotherapy alone.
Similar to the results of Klimo Jr. et al. [40], the study not
only found functional and survival outcomes to be superior
in the surgery plusradiotherapy group butalso reported that
surgical intervention was cost eﬀective, cementing the role
of surgery in the management of metastatic spine disease for
candidate patients.
Although surgery plus radiation has been shown to
be superior to radiation alone in a class I study, the role
of surgical intervention remains controversial due to the
diﬃculty of appropriate patient selection. Numerous factors
such as tumor type, extent of metastatic disease, spinal
stability, neurologic status, comorbid conditions, and life
expectancy are considered when evaluating a patient for
potential surgical candidacy [4, 15]. Furthermore, numerous
scoring systems such as that of Tokuhashi et al. [42]a n d
Tomita et al. [38]havebeencreated toguidepatientselection
and dictate the aggressiveness ofthe respective surgical inter-
vention. Unfortunately, the advances in surgical technique
that improved surgical outcomes in patients with metastatic
lesions required aggressive methods such as circumferential
decompression or combined(anterior, posterior, and lateral)
approaches that were only feasible in healthier patients
with respective longer life expectancies and thus were not
feasible for patients with numerous comorbid conditions or
contraindications such as ongoing chemotherapy [15].
Minimally invasive spine surgery was created with the
purpose of minimizing soft tissue surgical trauma and
thereby accelerating postoperative care [16, 18, 43, 44], with-
out a loss of surgical eﬀectiveness, and was thus applicable
to the management of metastatic spine disease in patients
not candidate for conventional surgical intervention. More
speciﬁcally, patientswith singleoradjacent levelinvolvement
with neurologic symptoms from spinal instability or neuro-
logical structure compression and a life expectancy of at least
3 months are considered candidate for MIS [15, 16, 18].
There are two main modalities of minimally inva-
sive spine surgery: endoscopic video-assisted thoracoscopic
surgery (VAST) and mini-open surgeries otherwise known
as minimal access spine surgery (MASS) [15]. VAST, ﬁrst
described in 1993 [45], allows for the visualization and
magniﬁcation of the entire ventral spine from T1 to T12,
therebyallowing fordecompression, reconstruction, andsta-
bilization similar to an open thoracotomy. However, unlike
an open thoracotomy, VAST has the advantage of decreased
pulmonary morbidity, preservation of chest wall motion,
decreased intercostal neuralgia, and avoidance of scapular
dysfunction [46]. Furthermore, VAST can be combined with
laparoscopic techniques to permit similar visualization and
manipulation of the lumbar spine [15, 29]. Despite advan-
tages, VAST has not become a widely adopted procedure
due to practical limitations such as a steep learning curve,
increased surgical time, relative diﬃculty in controllingInternational Journal of Surgical Oncology 7
intraoperative bleeding, and expensive equipment needed to
perform the procedure [15, 47].
MASS was ﬁrst described in 1997 [48] as a microsurgical
approachforperformingananteriorlumbarfusion,covering
all levels from L2 to S1. It has since become more popular
than VAST as an MIS modality as it is easier to learn, is
a more familiar exposure to most spine surgeons, permits
faster decompression of the spinal canal [23, 30, 49],
potentially allows for safer mobilization of neurovascular
structures, and provides three-dimensional direct vision
allowing for easier reconstruction of the anterior column
[50].Sinceitsintroduction, theprocedurehasbeenmodiﬁed
to permit access from T2 to S1 via a combination of mini-
openthoracotomy and/orretroperitoneal miniapproach [30,
49].
In this study, we performed a systematic review of
published literature to date with the goal of evaluating the
clinical eﬃcacy and safety of MIS in the setting of metastatic
spine disease. A total of 11 studies speciﬁcally reporting
outcomes of metastatic spine cases managed via MIS were
gathered. 5 of the studies, totaling 105 patients employed
VAST, and 6 of the studies, totaling 76 patients, employed
MASS. All of the collected studies were retrospective (Class
IV evidence), and two of the studies were case reports.
Althoughtraditionally excludedfrom systematic reviews, the
two case reports collected were included in our study due to
the scarcity of published studies reporting on the use of MIS
to treat metastatic spine lesions.
WeevaluatedtheclinicaleﬃcacyofMISforthetreatment
of metastatic vertebral lesions via neurological improvement
rate and pain alleviation rate outcome data. Collected data
from each study was compiled to yield median mean
neurological improvement (mNI) and median mean pain
alleviation rate (mPA). mNI for VAST was 100% (92%–
100%) and 95% (62.5%–100%) for MASS. mPA for VAST
was100%(94%–100%)and100%(62.5%–100%)forMASS.
The neurological improvement and pain alleviation rates are
similar to those provided by the Class I study conducted
by Patchell et al. that evaluated surgery plus radiotherapy
outcomes [41]. Given the high rates of neurological dys-
function and pain alleviation, the results suggest that both
VAST and MASS are eﬃcacious means of achieving pain and
neurological dysfunction relief through decompression and
stabilization.
Operative variables such as operative time, blood loss,
complication rate, and hospital stay are considered markers
of safety and practicality. Prolonged operating times are
associated with an increased amount of complications (i.e.,
higher wound infection rate) and costs [51]. High blood loss
leading to perioperative anemia leads to increased morbidity
(i.e., surgical site infections), mortality, length of stay, and
readmission rates [52]. Furthermore, patients with high
blood loss often require transfusions which are associated
with higher risks of infection, acute immune-mediated
hemolytic reactions, and gastrointestinal complaints [52].
Longer hospital stays result in higher costs and are indicative
of increased patient morbidity [15]. Smith et al. [47]
compiled median operative variables of 16 studies, totaling
746patients,reporting outcomedataforopenthoracotomies
performed in the setting of thoracolombar spine pathology.
Oneofthelimitationscommonlyassociated withMISproce-
dures is prolonged operative time. Data gathered contradicts
thisnotionand suggeststhatbothVASTand MASScollective
medianoperatingtimes(mMOT)comparefavorablytoopen
standard thoracotomy (ST) operating times collected by
Smith et al. [47] (VAST: 4.6 hours (2.6–6.5 hours); MASS:
3.7 hours (2.2–7 hours); ST: 4.65 hours (2.3–10.2 hours)).
Decreased complication rates, blood loss, and length of
stay are considered to be among the beneﬁts of MIS. This
was conﬁrmed by outcomes data compiled in our study
when compared to gathered data outcomes for ST [47].
Medianmeancomplicationrates(mCR)forVAST(0%(0%–
54%)) and MASS (9% (0%–24%)) compared favorably to
those of ST (30.5% (15%–94.4%)). Similarly, median mean
blood loss(mMBL) and median mean lengthofstay (mLOS)
for both VAST (mMBL: 1113mL (350–1677mL); mLOS:
7 days (6.5–7.5 days)) and MASS (mMBL: 905mL (227–
1200mL); mLOS: 5 days (4–6.25 days)) was decreased in
comparison to data gathered for ST [47] (mMBL: 2100mL
(460–3136mL); mLOS: 14.6 days (7.2–35.5 days)). It should
be noted that the paper by Huang et al. [23] included in
this review performed a direct retrospective comparison of
MOT, MBL, LOS, and CR for MASS versus ST and found no
signiﬁcant diﬀerence in rates for any of the latter. However,
the study did ﬁnd a signiﬁcant diﬀerence in the incidence
of patients that required at least a two-day admission to the
ICU postoperatively (MASS: 6.9% versus ST: 88%). If there
truly is not a diﬀerence in these operative variables, it is
possible that the potential beneﬁt of MIS is counteracted by
the more complicated nature of operating in patients with
metastatic spine disease [24]. This observation was present
in the study included by Payer and Sottas [30]i nw h i c h
mean blood loss, operative time, and complication rates
were higher in patients being operated for spinal tumors
versus those operated on the spine for pathology other than
tumor.
5.Conclusions
A systematic review of the literature yielded Class IV data
suggesting that both VAST and MASS MIS modalities are
eﬃcacious means of achieving neurological improvement
and alleviating pain in the treatment of metastatic spine
disease. However, the magnitude of neurological improve-
ment and/or pain alleviation cannot be accurately quantiﬁed
by such retrospective studies. Such studies suggest that
minimally invasive surgery for metastatic spine disease oﬀers
decreased blood loss, operative time, and complication rates
in comparison to standard open spine surgery. Furthermore,
these studies also suggest that MIS implementation was not
limited by increased operative times. Nonetheless due to
the paucity of studies and low class of available evidence,
the ability to draw comprehensive conclusions is limited.
Minimally invasive surgery thus remains a viable option
for the treatment of spinal metastases. Future investiga-
tions should be conducted comparing standard surgery
versus minimally invasive surgery in a prospective fash-
ion.8 International Journal of Surgical Oncology
References
[ 1 ]M .J .H a y a t ,N .H o w l a d e r ,M .E .R e i c h m a n ,a n dB .K .
Edwards, “Cancer statistics, trends, and multiple primary
cancer analyses from the surveillance, epidemiology, and end
results (SEER) program,” Oncologist, vol. 12, no. 1, pp. 20–37,
2007.
[2] M. P. Steinmetz, A. Mekhail, and E. C. Benzel, “Management
of metastatic tumors of the spine: strategies and operative
indications,” Neurosurgical Focus, vol. 11, no. 6, p. e2, 2001.
[3] W. B. Jacobs and R. G. Perrin, “Evaluation and treatment of
spinal metastases: an overview,” Neurosurgical Focus,v o l .1 1 ,
no. 6, p. e10, 2001.
[ 4 ] D .M .S c i u b b a ,R .J .P e t t e y s ,M .B .D e k u t o s k ie ta l . ,“ D i a g n o s i s
andmanagementofmetastaticspinedisease:areview,”Journal
of Neurosurgery: Spine, vol. 13, no. 1, pp. 94–108, 2010.
[5] D. M. Sciubba and Z. L. Gokaslan, “Diagnosis and manage-
ment of metastatic spine disease,” Surgical Oncology, vol. 15,
no. 3, pp. 141–151, 2006.
[6] S. Helweg-Larsen and P. S. Sorensen, “Symptoms and signs
in metastatic spinal cord compression: a study of progression
from ﬁrst symptom until diagnosis in 153 patients,” European
Journal of Cancer PartA: GeneralTopics,vol.30,no.3,pp.396–
398, 1994.
[7] F. Bach, B. H. Larsen, K. Rohde et al., “Metastatic spinal cord
compression. Occurrence, symptoms, clinical presentations
and prognosis in 398 patients with spinal cord compression,”
Acta Neurochirurgica, vol. 107, no. 1-2, pp. 37–43, 1990.
[ 8 ]Y .M .V a nD e rL i n d e n ,S .P .D .S .D i j k s t r a ,E .J .A .V o n k ,C .
A. M. Marijnen, and J. W. H. Leer, “Prediction of survival in
patients withmetastasesin thespinalcolumn:results basedon
arandomizedtrialofradiotherapy,” Cancer,vol.103,no.2,pp.
320–328, 2005.
[9] J. S. Cole and R. A. Patchell, “Metastatic epidural spinal cord
compression,”TheLancetNeurology,vol.7,no.5,pp.459–466,
2008.
[ 1 0 ]T .F .W i t h a m ,Y .A .K h a v k i n ,G .L .G a l l i a ,J . - P .W o l i n s k y ,
and Z. L. Gokaslan, “Surgery insight: current management
of epidural spinal cord compression from metastatic spine
disease,” Nature Clinical Practice Neurology,v o l .2 ,n o .2 ,p p .
87–94, 2006.
[11] R.HarelandL.Angelov, “Spinemetastases:current treatments
and future directions,” European Journal of Cancer, vol.46, no.
15, pp. 2696–2707, 2010.
[12] R. H. M. A. Bartels, Y. M. Van Der Linden, and W. T. A. Van
Der Graaf, “Spinal extradural metastasis: review of current
treatment options,” CA Cancer Journal for Clinicians, vol. 58,
no. 4, pp. 245–259, 2008.
[13] R. H. M. A. Bartels, T. Feuth, R. Van Der Maazen et
al., “Development of a model with which to predict the
life expectancy of patients with spinal epidural metastasis,”
Cancer, vol. 110, no. 9, pp. 2042–2049, 2007.
[ 1 4 ]D .A .L o b l a w ,N .J .L a p e r r i e r e ,a n dW .J .M a c k i l l o p ,“ A
population-based study ofmalignantspinalcord compression
in Ontario,” Clinical Oncology, vol. 15, no. 4, pp. 211–217,
2003.
[15] O. Oﬂuoglu, “Minimally invasive management of spinal
metastases,” Orthopedic Clinics of North America, vol. 40, no.
1, pp. 155–168, 2009.
[ 1 6 ] M .J .B i n n i n g ,O .N .G o t t f r i e d ,P .K l i m oJ r . ,a n dM .
H. Schmidt, “Minimally invasive treatments for metastatic
tumors of the spine,” Neurosurgery Clinics of North America,
vol. 15, no. 4, pp. 459–465, 2004.
[17] A. S. Kanter and P. V. Mummaneni,“Minimally invasive spine
surgery,” Neurosurgical Focus,v o l .2 5 ,n o .2 ,a r t i c l en o .E 1 ,
2008.
[18] S. Keshavarzi, M. S. Park, H. E. Aryan et al., “Minimally inva-
sive thoracic corpectomy and anterior fusion in a patient with
metastatic disease: case report and review of the literature,”
Minimally Invasive Neurosurgery, vol. 52, no. 3, pp. 141–143,
2009.
[19] P. C. McAfee, F. M. Phillips, G. Andersson et al., “Minimally
invasive spine surgery,” Spine, vol. 35, no. 26 Suppl, pp. S271–
273, 2010.
[20] D. Rosenthal, G. Marquardt, R. Lorenz, and M. Nichtweib,
“Anterior decompressionandstabilizationusingamicrosurgi-
cal endoscopictechnique formetastatictumorsofthe thoracic
spine,” Journal of Neurosurgery, vol. 84, no. 4, pp. 565–572,
1996.
[21] R. F. McLain, “Spinal cord decompression: an endoscopically
assisted approach for metastatic tumors,” Spinal Cord,v o l .3 9 ,
no. 9, pp. 482–487, 2001.
[22] C. A. Logroscino, L. Proietti, and F. C. Tamburrelli, “Mini-
mally invasive spine stabilisation with long implants,” Euro-
pean Spine Journal, vol. 18, no. 1, pp. S75–S81, 2009.
[23] T. J. Huang, R. W. W. Hsu, Y. Y. Li, and C. C. Cheng,
“Minimal access spinal surgery (MASS) in treating thoracic
spine metastasis,”Spine, vol. 31, no. 16, pp. 1860–1863, 2006.
[24] T. J. Huang, R. W. W. Hsu, C. W. Sum, and H. P. Liu,
“Complications in thoracoscopic spinal surgery: a study of 90
consecutive patients,” Surgical Endoscopy,v o l .1 3 ,n o .4 ,p p .
346–350, 1999.
[ 2 5 ]J .L eH u e c ,E .L e s p r i t ,J .G u i b a u d ,N .G a n g n e t ,a n dS .
Aunoble, “Minimally invasive endoscopic approach to the
cervicothoracic junction for vertebral metastases: report of
two cases,”European Spine Journal, vol.10,no.5, pp. 421–426,
2001.
[26] R.J.Mobbs,P.Nakaji,B.J.Szkandera,andC.Teo,“Endoscopic
assisted posterior decompression for spinal neoplasms,” Jour-
nal of Clinical Neuroscience, vol. 9, no. 4, pp. 437–439, 2002.
[27] M. M¨ uhlbauer, W.Pﬁsterer, R. Eyb, and E. Knosp,“Minimally
invasive retroperitoneal approach for lumbar corpectomy and
anterior reconstruction. Technical note,” Journal of Neuro-
surgery, vol. 93, no. 1, pp. 161–167, 2000.
[28] H. Deutsch, T. Boco, and J. Lobel, “Minimally invasive
transpedicular vertebrectomy for metastatic disease to the
thoracicspine,”Journal ofSpinalDisorders andTechniques,v ol.
21, no. 2, pp. 101–105, 2008.
[29] P. Kan and M. H. Schmidt, “Minimally invasive thoracoscopic
approach for anterior decompression and stabilization of
metastatic spine disease,” Neurosurgical Focus,v o l .2 5 ,n o .2 ,
article no. E8, 2008.
[30] M. Payer and C. Sottas, “Mini-open anterior approach for
corpectomy in the thoracolumbar spine,” Surgical Neurology,
vol. 69, no. 1, pp. 25–31, 2008.
[ 3 1 ]A .T a g h v a ,K .W .L i ,J .C .L i u ,Z .L .G o k a s l a n ,a n dP .C .H s i e h ,
“Minimally invasive circumferential spinal decompression
and stabilization for symptomatic metastatic spine tumor:
technical case report,” Neurosurgery, vol. 66, no. 3, pp. E620–
E622, 2010.
[32] K. D. Harrington, “Anterior cord decompression and spinal
stabilization for patients with metastatic lesions of the spine,”
Journal of Neurosurgery, vol. 61, no. 1, pp. 107–117, 1984.
[33] R. J. Stark, R. A. Henson, and S. J. W. Evans, “Spinal
metastases. A retrospective survey from a general hospital,”
Brain, vol. 105, no. 1, pp. 189–213, 1982.International Journal of Surgical Oncology 9
[34] R.M.ShermanandJ.P.Waddell,“Laminectomyformetastatic
epiduralspinalcordtumors.Posteriorstabilization,radiother-
apy, and preoperative assessment,” Clinical orthopaedics and
related research, no. 207, pp. 55–63, 1986.
[35] H.Hirabayashi,S.Ebara,T.Kinoshitaet al.,“Clinicaloutcome
and survival after palliative surgery for spinal metastases:
palliative surgery in spinal metastases,” Cancer, vol. 97, no. 2,
pp. 476–484, 2003.
[36] R. George, J. Jeba, G. Ramkumar, A. G. Chacko, M. Leng,
and P. Tharyan, “Interventions for the treatment of metastatic
extradural spinal cord compression in adults,” Cochrane
Database of Systematic Reviews, no. 4, Article ID CD006716,
2008.
[37] A. Ibrahim, A. Crockard, P. Antonietti et al., “Does spinal
surgery improve the quality of life for those with extradural
(spinal) osseous metastases? An international multicenter
prospective observational study of 223 patients: invited sub-
mission from the Joint Section Meeting on Disorders of
the Spine and Peripheral Nerves, March 2007,” Journal of
Neurosurgery: Spine, vol. 8, no. 3, pp. 271–278, 2008.
[38] K. Tomita, N. Kawahara, T. Kobayashi, A. Yoshida, H.
Murakami, and T. Akamaru, “Surgical strategy for spinal
metastases,” Spine, vol. 26, no. 3, pp. 298–306, 2001.
[39] J. P. Constans, E. De Divitiis, and R. Donzelli, “Spinal
metastases with neurological manifestations. Review of 600
cases,” Journal of Neurosurgery, vol. 59, no. 1, pp. 111–118,
1983.
[40] P. Klimo Jr., C. J. Thompson, J. R. W. Kestle, and M. H.
Schmidt, “A meta-analysis of surgery versus conventional
radiotherapy for the treatment of metastatic spinal epidural
disease,” Neuro-Oncology, vol. 7, no. 1, pp. 64–76, 2005.
[41] R. A. Patchell, P. A. Tibbs, W. F. Regine et al., “Direct
decompressive surgical resection in the treatment of spinal
cord compression caused by metastatic cancer: a randomised
trial,” Lancet, vol. 366, no. 9486, pp. 643–648, 2005.
[42] Y. Tokuhashi, H. Matsuzaki, S. Toriyama, H. Kawano, and S.
Ohsaka, “Scoring system for the preoperative evaluation of
metastatic spine tumor prognosis,” Spine, vol. 15, no. 11, pp.
1110–1113, 1990.
[43] J. J. Regan, H. Yuan, and P. C. McAfee, “Laparoscopic fusion
of the lumbar spine: minimally invasive spine surgery: a
prospective multicenter study evaluating open and laparo-
scopiclumbarfusion,”Spine,vol.24,no.4, pp. 402–411,1999.
[44] J. J. Regan, R. J. Aronoﬀ,D .D .O h n m e i s s ,a n dD .K .S e n g u p t a ,
“Laparoscopic approach to L4-L5 for interbody fusion using
BAK cages: experience in the ﬁrst 58 cases,” Spine,v o l .2 4 ,n o .
20, pp. 2171–2174, 1999.
[ 4 5 ]M .J .M a c k ,J .J .R e g a n ,W .P .B o b e c h k o ,a n dT .E .A c u ﬀ,
“Application of thoracoscopy for diseases of the spine,” Annals
of Thoracic Surgery, vol. 56, no. 3, pp. 736–738, 1993.
[46] P. P. Han, K. Kenny, and C. A. Dickman, “Thoracoscopic
approaches to the thoracic spine: experience with 241 surgical
procedures,” Neurosurgery, vol. 51, no. 5, pp. 88–95, 2002.
[ 4 7 ] W .D .S m i t h ,E .D a k w a r ,T .V .L e ,G .C h r i s t i a n ,S .S e r r a n o ,a n d
J. S. Uribe, “Minimally invasive surgery for traumatic spinal
pathologies:a mini-open, lateral approach in the thoracic and
lumbar spine,” Spine, vol. 35, supplement 26, pp. S338–S346,
2010.
[48] H. M. Mayer, “A new microsurgical technique for minimally
invasive anterior lumbar interbody fusion,” Spine, vol. 22, no.
6, pp. 691–700, 1997.
[49] T. Kossmann,D. Jacobi, and O. Trentz, “The use of a retractor
system (SynFrame) for open, minimal invasive reconstruction
of the anterior column of the thoracic and lumbar spine,”
European Spine Journal, vol. 10, no. 5, pp. 396–402, 2001.
[50] R. M. Lin, K. Y. Huang, and K. A. Lai, “Mini-open anterior
spine surgery for anterior lumbar diseases,” European Spine
Journal, vol. 17, no. 5, pp. 691–697, 2008.
[51] T. D. Jackson, J. J. Wannares, R. T. Lancaster, D. W. Rattner,
and M. M. Hutter, “Does speed matter? The impact of
operative time on outcome in laparoscopic surgery,” Surgical
Endoscopy. Pubmed ID: 21298533.
[ 5 2 ]A .F .P u l lt e rG u n n e ,R .L .S k o l a s k y ,H .R o s s ,C .J .H .M .
van Laarhoven, and D. B. Cohen, “Inﬂuence of perioperative
resuscitation status on postoperative spine surgery complica-
tions,” Spine Journal, vol. 10, no. 2, pp. 129–135, 2010.